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Background: Increased plasma levels of proteasome have been associated with various neoplasms, especially
myeloid malignancies. Little is known of the cellular origin and release mechanisms of such proteasome.
We recently identified and characterized a novel particulate cytoplasmic structure (PaCS) showing selective
accumulation of ubiquitin-proteasome system (UPS) components. PaCSs have been reported in some epithelial
neoplasms and in two genetic disorders characterized by hematopoietic cell dysplasia and increased risk of
leukemia. However, no information is available about PaCSs in hematopoietic neoplasms.
Methods: PaCSs were investigated by ultrastructural, immunogold, and immunofluorescence analysis of bone
marrow (BM) biopsies and peripheral blood (PB) cell preparations of 33 consecutive, untreated, or relapsed patients
affected by different hematopoietic neoplasms. BM and PB samples from individuals with non-neoplastic BM or
healthy donors were studied as controls. Granulocytes and platelet proteasome content was measured by
immunoblotting and plasma proteasome levels by ELISA.
Results: PaCSs with typical, selective immunoreactivity for polyubiquitinated proteins and proteasome were
widespread in granulocytic cells, megakaryocytes, and platelets of patients with myeloproliferative neoplasms
(MPN). In acute myeloid leukemia and myelodysplastic syndromes (MDS), PaCSs were only occasionally detected in
blast cells and were found consistently in cells showing granulocytic and megakaryocytic maturation. Conversely,
PaCSs were poorly represented or absent in non-neoplastic hematopoietic tissue or lymphoid neoplasms. In MPN
granulocytes and platelets, the presence of PaCSs was associated with increased amounts of proteasome in cell
lysates. PaCSs were often localized in cytoplasmic blebs generating PaCSs-filled plasma membrane vesicles observable
in the BM intercellular space. In MPN and MDS, accumulation of PaCSs was associated with significant increase in
plasma proteasome. Immunogold analysis showed that PaCSs of myeloid neoplasia selectively concentrated the
chaperone proteins Hsp40, Hsp70, and Hsp90.
Conclusions: PaCSs accumulate in cells of myeloid neoplasms in a lineage- and maturation-restricted manner; in
particular, they are widespread in granulocytic and megakaryocytic lineages of MPN patients. PaCSs development was
associated with excess accumulation of polyubiquitinated proteins, proteasome, and chaperone molecules, indicating
impairment of the UPS-dependent protein homeostasis and a possible link with Hsp90-related leukemogenesis. A
mechanism of PaCSs discharge by leukemic cells could contribute to increased plasma proteasome of MPN and MDS.
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Increased cellular expression and activity of proteasome
have been reported in a variety of neoplasms, including
hematological, epithelial, and neurological tumors [1–5].
This has led to the proposal of proteasome inhibitors as
antineoplastic therapy, with clinically relevant results in
some tumors, such as plasma cell myeloma and mantle
cell lymphoma [6, 7]. Both epithelial and hemopoietic
neoplasms have been associated with increased plasma
levels of proteasome which were disease type, stage, and
therapy sensitive [8–11]. However, little is known about
the intracellular origin and release mechanisms of this
increase in plasma proteasome in neoplastic diseases. It
remains unclear whether the proteasome in neoplastic
cells is passively released during cell lysis and apoptosis,
or whether some specific, more regulated, release mech-
anism exists, which may better account for the selectivity
of the changes in plasma proteasome level [9].
Proteasome has been reported in exosomes [12], which
are small (50–100 nm) vesicles of endosomal origin that
are released by several cell types, including non-
pathological blood cells [13, 14] and neoplastic cells [15].
The involvement in proteasome release of other extracel-
lular vesicles, such as plasma-membrane-derived mic-
rovesicles, also called ectosomes or microparticles, has
recently been suggested [16]. Besides proteasome compo-
nents, neoplastic cells accumulate excessive amounts of
polyubiquitinated proteins [2, 4, 5, 17], the proteasome
elective substrate. Limited information is available on the
fate of such proteins and whether they are totally de-
graded inside neoplastic cells or at least in part discharged
extracellularly together with proteasome components.
We recently identified and characterized a novel par-
ticulate cytoplasmic structure (PaCS) that concentrates
polyubiquitinated proteins and proteasome in some
epithelial neoplasms and related preneoplastic lesions
[5, 7, 17, 18], as well as in two genetic disorders charac-
terized by hematopoietic cell dysplasia and increased risk
of leukemia [19, 20]. However, the presence of PaCSs in
hematological neoplasms has never been investigated.
Here, we demonstrate that PaCSs accumulate in differ-
ent forms of myeloid neoplasia in a maturation- and
lineage-specific manner. Our findings suggest that a mech-
anism of PaCSs discharge by leukemic cells contribute to
increased plasma proteasome in myeloid neoplasms.
Results
PaCSs in hematological neoplasms
Combined ultrastructural and immunogold analysis
showed that PaCSs were extensive in bone marrow (BM)
of patients with myeloproliferative neoplasms (MPN),
including chronic myelogenous leukemia (CML), polycy-
themia vera (PV), essential thrombocythemia (ET), and
primary myelofibrosis (PMF). PaCSs appeared as focalaccumulations of barrel-like particles, mostly ~13 nm
thick and 13–20 nm long, filling cytoplasmic areas
devoid of cytoskeleton or cellular organelles such as
mitochondria, endoplasmic reticulum, Golgi complex,
and lysosomes, while being often surrounded by
ribosomes (Figs. 1 and 2). Similarly to PaCSs previously
observed in other disorders [17–20], PaCSs of MPNs
showed selective immunogold reactivity for polyubiquiti-
nated proteins and 19S and 20S proteasome, with more
than 20-fold higher concentration of gold particles inside
PaCSs than in the cytoplasm outside PaCSs. Notably,
PaCSs were prominent in granulocytic cells at different
stages of maturation (from myelocytes to neutrophil
granulocytes) and in mature megakaryocytes (Figs. 1a–c
and 2b), whereas no PaCSs were found in erythroblasts,
lymphocytes, plasma cells, or macrophages. In the cases
of PMF and ET, we occasionally observed PaCSs in BM
stromal cells, including fibroblasts, which were increased
in the presence of BM fibrosis (Fig. 2c).
For most MPN patients, the analysis was extended to
peripheral blood (PB) cells (Table 1). In PB cell prepara-
tions, PaCSs were also found extensively in granulocytic
cells and in platelets (Figs. 1d, e and 2a), whereas erythro-
cytes, lymphocytes, and monocytes presented no PaCSs.
Consistent with these findings, Western blot analysis
demonstrated that protein extracts of both granulocytes
and platelets from patients with MPN presented markedly
increased levels of 20S proteasome with respect to healthy
subjects (Fig. 3a). The PB samples from the two patients
with relapsed CML presented PaCSs with distribution,
morphology, and immunoreactivity pattern similar to
those of untreated CML subjects.
Previous correlative confocal and electron microscopy
demonstrated that PaCSs are recognized also by immuno-
fluorescence for 19S, 20S, or polyubiquitinated proteins on
osmium-fixed semithin resin sections [5, 19]. As expected,
immunofluorescence analysis confirmed that BM cells of
patients with MPNs presented cytoplasmic areas with
strong immunoreactivity to UPS components (Fig. 3b).
A prominent feature of PaCS-positive BM cells from
MPN patients was the presence of pleomorphic PaCS-
filled and organelle-free cytoplasmic membrane blebs of
varying size and shape. These blebs apparently released
PaCS-filled round to ovoid vesicles (0.1–1 μm in diameter)
that were fully detached from the cytoplasm and freely
floating in the BM intercellular spaces (Figs. 1a, b and 4a,
b). In some cells with PaCSs, many autophagic vesicles,
characteristically enveloped by double membranes, were
also seen in the cytoplasm (Fig. 1c–e). A minority of such
vesicles stored PaCS-type particles and contained polyubi-
quitinated proteins and proteasome immunoreactivity,
which strongly suggests that PaCSs were partly involved in
the autophagic process (Fig. 1c). Known ultrastructural
signs of apoptosis [19, 21], such as chromatin compaction,
Fig. 1 PaCSs are widespread in hematopoietic cells of patients with untreated CML. a Several BM cells of the granulocytic lineage display
cytoplasmic collections of barrel-like particles, enlarged in a1 and a2 to show the particles and their 20S proteasome (β5i subunit) immunogold
reactivity. PaCS-filled blebs (arrowheads) and cell-detached vesicles (arrows) are devoid of cytoplasmic organelles. A cytoskeleton-rich cytoplasmic
network (arrowheads in a1) separates PaCSs from the cytoplasmic membrane; the cytoskeletal network is largely lost in some detached vesicles
(arrow in a1) undergoing degeneration while still preserving proteasome reactivity. b A PaCS-filled cellular bleb (b) and isolated vesicles (b1, b2)
in BM extracellular space show PaCS-restricted immunogold reactivity for polyubiquitinated proteins (FK1 antibody). c A myelocyte shows large,
FK1-reactive PaCSs and several FK1-negative autophagic vesicles. The largest vesicle is enlarged in c1 to show its enveloping double membrane
and its unusual storage of PaCS-type particles, as well as FK1-immunoreactive polyubiquitinated proteins comparable with those of adjacent
PaCSs; a likely sign of ongoing PaCS autophagy. The asterisk indicates an erythroblast showing no PaCSs; s indicates stromal cell processes.
d, e PB granulocytic cell (d, enlarged in d1) and platelet (e) from a CML patient showing PaCSs reactive for polyubiquitinated proteins
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plasm with no recognizable organelles were observed only
occasionally in MPN cells, irrespectively of the presence of
PaCS, blebs/ectosomes, or autophagic vesicles.
To gain insight into the respective role of PaCSs and
autophagic vesicles, we performed in MPN cells cyto-
chemical assays for proteins known to be associated with
UPS function or autophagy. Hsp40, Hsp70, and Hps90
chaperones were selectively concentrated inside PaCSs
(Fig. 4a–c), while the co-chaperone Bag 6 had sparse
cytoplasmic reactivity, without preferential concentra-
tion in PaCSs (Fig. 4d). Autophagic vesicles showed
reactivity for LC3A protein, a known autophagy marker
[22], to which PaCSs showed no reactivity (Fig. 4e).
Unlike MPN cells, BM blasts of the 8 patients with
acute myeloid leukemia (AML) had no PaCSs or only a
few small PaCSs, and they had no autophagic vesicles or
PaCS-filled blebs (Fig. 5a–c) In BM biopsies of AML
patients, only the cells with morphological features ofgranulocytic precursors or megakaryocytes showed
PaCSs. The findings on the relapsed AML patient were
similar to those of the 7 untreated cases. Among the 8
patients with myelodysplastic syndromes (MDS), PaCSs
were found in BM cells of the granulocytic and megakar-
yocytic lineages, as well as in PB granulocytes and plate-
lets of all the analyzed patients (Fig. 5d, e). A notable
exception was represented by BM granulocytic and
megakaryocytic precursors with most prominent signs of
cytoplasmic immaturity (abundant ribosomes, paucity of
cytoplasmic organelles, and reduced specific secretory
granules), which usually lacked or showed only occa-
sional small PaCSs. Similarly, blast cells of the patients
with refractory anemia with excess blasts had no PaCSs
(data not shown). These findings suggest that, within the
myeloid neoplastic clones, PaCSs are widespread in cells
with preserved, although aberrant, maturation toward
granulocytic or megakaryocytic lineages, whereas they
do not develop in cells with maturation arrest at the
Fig. 2 PaCSs are widespread in cells of Philadelphia-negative MPN. a PaCSs in PB platelets of a patient with PV, enlarged in the inset to show
barrel-like particles and FK1 immunoreactivity. b BM megakaryocyte with small FK1-reactive peripheral PaCSs, enlarged in the inset, from a patient
with ET. c A fibroblast (f) with FK1-positive PaCSs and two intrasinusoidal erythroblasts (asterisks) are found in the BM of an individual with PMF.
The fibroblast is enlarged in c1 and c2 to show the intracellular procollagen granules (arrows), juxtafibroblast collagen fibers (arrowheads), and
FK1-positive PaCSs
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precursor. PaCSs of MDS presented the same immunore-
activity pattern of those observed in MPN; in particular,
PaCSs of MDS patients also showed selective concentra-
tion of Hsp40, Hsp70, and Hps90 (data not shown). More-
over, the presence of PaCS-filled cytoplasmic membrane
blebs, associated with PaCS-filled vesicles freely floating in
the intercellular space, has been frequently observed also
in BM of the MDS subjects (Fig. 5d).
There were no PaCSs in BM biopsies of 4 patients
with chronic B-cell leukemia or plasma cell myeloma
(Additional file 1: Figure S1). Myeloma plasma cells
showed sparse proteasome immunoreactivity in close
association with the extensively developed rough endo-
plasmic reticulum (RER) cisternae, some of which were
dilated and filled with compact, amorphous material oc-
casionally forming Russel or Dutcher bodies (Additional
file 1: Figure S1e, f ).
PaCSs in non-neoplastic BM and PB
Ultrastructural analysis of non-neoplastic BM biopsies
from 6 individuals, combined with immunogold labeling
for polyubiquitinated proteins and 20S and 19S prote-
asome, showed no PaCSs in hematopoietic or stromal
cells (Additional file 1: Figure S2a–e). There were occa-
sional small PaCSs in cells of the granulocytic or megakar-
yocytic lineages inside areas with increased macrophages,
eosinophils, plasma cells, or lymphocytes, likely due to
focal inflammation. There was increased accumulation of
polyubiquitinated proteins in the cytoplasm of somemature BM granulocytes, sometimes concentrated in
cytoplasmic blebs; particularly in minute clear, non-
particulate “areolae,” as previously described [19]
(Additional file 1: Figure S2f). PB from healthy volunteers
showed small scanty PaCSs in 10–20 % of granulocytes
and platelets (Table 2; Additional file 1: Figure S2g, h),
consistent with previous observations on PB granulocytes
and platelets obtained from healthy subjects [19, 20].
Quantification of PaCSs in PB cells from CML patients and
healthy controls
To confirm and quantify the increased presence of PaCSs
as a feature of hematopoietic cells in MPN, we performed
software-assisted image analysis of electron microscopy
preparations of PB granulocytes and platelets from 4 con-
secutive CML patients and three healthy subjects. The
morphometric features of PaCSs are reported in Table 2.
In particular, the mean area of cytoplasm occupied by
PaCSs was 6.5-fold higher in CML than control granulo-
cytes (P < 0.01) and 8.4-fold higher in CML than control
platelets (P < 0.001). For both granulocytes and platelets,
the increased presence of PaCSs in CML patients
compared with healthy subjects resulted from a higher
percentage of cells with PaCSs and a higher number of
PaCSs per cell.
Plasma proteasome levels in patients with MPN, MDS,
and healthy controls
Plasma proteasome levels were measured in 6 patients
with CML (patients 3–8 in Table 1), 4 subjects with PV
Table 1 Study population and samples that were investigated
for the presence of PaCSs




1 M/64 CML, BCR/ABL positive U BM, PB
2 M/38 CML, BCR/ABL positive U BM
3 F/24 CML, BCR/ABL positive U PB
4 F/79 CML, BCR/ABL positive U PB
5 F/78 CML, BCR/ABL positive U PB
6 F/65 CML, BCR/ABL positive U PB
7 F/79 CML, BCR/ABL positive R PB
8 F/74 CML, BCR/ABL positive R PB
9 F/45 ET U BM, PB
10 M/56 PV U BM, PB
11 M/79 PV U BM, PB
12 M/68 PMF U BM, PB
13 F/57 PMF U BM
14 F/43 AML not otherwise specified,
acute myelomonocytic
leukemia (A mutation of
NPM1 and internal tandem
duplication of FLT3)
U BM
15 M/64 AML not otherwise specified,
acute myelomonocytic
leukemia (A mutation of
NPM1)
U BM
16 F/64 AML not otherwise specified,
acute monoblastic/
monocytic leukemia
(A mutation of NPM1)
U BM
17 F/48 AML not otherwise
specified, AML with minimal
differentiation
(A mutation of NPM1)
U BM
18 M/64 AML not otherwise
specified, AML with minimal
differentiation
(A mutation of NPM1)
U BM








21 M/35 AML not otherwise specified,
AML with minimal
differentiation (internal
tandem duplication of FLT3)
R BM
22 M/74 MDS, refractory cytopenia
with multilineage dysplasia
U BM, PB
23 M/69 MDS, refractory cytopenia
with multilineage dysplasia
U BM, PB
24 F/35 MDS, refractory anemia with
excess blasts
U BM, PB
25 M/75 MDS, refractory cytopenia
with multilineage dysplasia
U PB
Table 1 Study population and samples that were investigated
for the presence of PaCSs (Continued)
26 M/75 MDS, refractory cytopenia
with multilineage dysplasia
U PB
27 M/52 MDS, refractory anemia with
excess blasts
U PB
28 M/4 MDS, childhood MDS U BM
29 F/37 MDS, refractory
thrombocytopenia
U BM, PB
30 M/49 Hairy cell leukemia U BM
31 F/50 Chronic lymphocytic
leukemia
U BM, PB
32 M/50 Plasma cell myeloma U BM
33 M/80 Plasma cell myeloma U BM
aAccording to WHO Classification of Tumors of Hematopoietic and Lymphoid
Tissue. Lyon, France: IARC, 2008
U untreated, R relapsed, BM bone marrow iliac biopsy, PB cell preparations of
peripheral blood granulocytes, mononuclear cells, and platelets
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and 10 healthy subjects. Compared to healthy individuals,
proteasome levels were significantly higher in CML
patients (mean ± standard deviation: CML 12.2 ± 7.6
μg/mL vs. healthy subjects 3.3 ± 2.0 μg/mL, P < 0.01), in
patients with BCR/ABL-negative MPN (14.6 ± 6.7 μg/mL,
P < 0.001 vs. healthy controls), as well as in MDS indivi-
duals (17.5 ± 14.3 μg/mL, P < 0.01 vs. healthy controls).
Discussion
This study showed that PaCSs, the recently identified
cytoplasmic structures rich in proteasomes and polyubi-
quitinated proteins [18, 23], were expressed in myeloid
neoplasia. In particular, PaCSs were widespread in BM
and PB cells of MPN patients. In these cases, PaCSs
were restricted to cells of the granulocytic lineage, mega-
karyocytes, and platelets but were absent in immature
blasts as well as in erythroid cells. Among AML and
MDS patients, PaCSs were absent or scarce and small in
blast cells, while they were detected in cells undergoing
granulocytic or megakaryocytic maturation. No PaCSs
were found in B-cell chronic leukemia, plasma cell mye-
loma, or non-neoplastic BM. Thus, as already observed
in fetal tissues [17] and solid neoplasms [5], in myeloid
neoplasms, the development and accumulation of PaCSs
appears associated with differentiation along specific
hematopoietic lineages. These may be instrumental in
allowing certain cytokines or growth factors to induce
PaCSs through lineage-specific receptors or signalling
pathways [23]. This mechanism of lineage specificity
may explain why neoplasms with lymphoid or plasma
cell differentiation are not associated with development
of these cytoplasmic structures.
PaCSs arise from rearrangement of cytosolic UPS
components from their usually diffuse pattern in most
Fig. 3 In MPN patients, the proteasome levels are markedly increased in granulocytes and platelet lysates, while immunofluorescence for UPS
reveals PaCSs-like structures in BM cells of MPN patients. a Accumulation of PaCSs in MPN granulocytes and platelets was associated with markedly
increased levels of 20S proteasome in cell lysates. Representative example of Western blot analysis of the 20S proteasome in blood granulocytes and
platelet lysates from two healthy subjects (HS) or from patient 3, affected by CML, or patient 8, affected by PV. Granulocyte and platelet lysates were
separated on a 12 % SDS/polyacrylamide gel and transferred to nitrocellulose. Membranes were probed with an antibody against 20S proteasome
(α6 subunit). Beta-actin was used as equal loading control. b Confocal microscopy after immunofluorescence staining for 20S proteasome identifies
several cytoplasmic areas with strong 20S signal (green) in the BM biopsy of a CML patient; background BM structure is recognized by phase-contrast
microscopy. b1, b2 Two sections from the same specimen show 20S proteasome (b1) and polyubiquitinated proteins (b2) immunoreactive cytoplasmic
areas in CML cells under confocal microscopy; note in b1 several 20S-positive cell blebs (arrowheads) and cell detached vesicles (arrows)
Fig. 4 PaCSs present selective immunoreactivity for chaperone molecules. a–e BM MPN cells show selective PaCS immunoreactivity for Hsp40
(a), Hsp70 (b), and Hsp90 (c, c1, and inset), although not for Bag6 (d). Autophagic vesicles remain unreactive to Hsp70 (b) and Hsp90 (c, c1), while
reacting with LC3A antibody (e), where an adjacent small PaCS (arrow) does not react. mi plasma membrane invaginations in the process of
severing PaCS-filled blebs from their cell of origin
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Fig. 5 PaCSs are poorly represented in AML whereas are present in MDS cells. a–c BM of AML patients. No PaCSs are found in blast cells shown
in (a) (asterisk) and (b), while a small FK1-reactive PaCS (arrowheads) is being formed in a ribosome-rich area of another blast (c), also showing
focal differentiation of endoplasmic reticulum (arrows). rm reactive macrophage. d BM micromegakaryocyte of a patient with MDS (refractory
anemia with multilineage dysplasia) showing small peripheral PaCSs (arrows), some of which enter into blebs and free vesicles (d1). e PB neutrophil
granulocyte of a patient with MDS (refractory anemia with multilineage dysplasia) with several PaCSs, one of which is enlarged in the inset to recognize
FK1 immunogold reactivity. Note in the lower right corner (arrowhead) a PaCS in an adjacent platelet
Pecci et al. Journal of Hematology & Oncology  (2015) 8:71 Page 7 of 11normal adult cells [17, 24] to a focal concentration in
distinctive, particle-rich areas [18, 23]. The driving
factors, mechanisms, and biological significance of this
change remain largely unknown. However, PaCS-
developing cells have several points in common, which
may include an ongoing differentiation process coupled
with enhanced proliferation (as found in both fetal and
neoplastic cells) [17], chronic infection [18], or even
stimulation by cell-specific growth factors and interleu-
kins [23]. All such conditions are known to enhanceTable 2 Morphometric features of PaCSs in granulocytes and












CML 67.8 ± 9.1** 7.1 ± 1.9** 53.8 ± 28.4* 8.2 ± 4.5*
Healthy
subjects
15.3 ± 12.8 1.1 ± 0.5 5.1 ± 3.9 0.7 ± 0.5
Platelets
CML 56.5 ± 5.0*** 7.6 ± 1.2*** 47.4 ± 18.7* 0.9 ± 0.3*
Healthy
subjects
18.2 ± 4.8 0.9 ± 0.3 11.5 ± 7.6 0.2 ± 0.1
Data are presented as means ± SD
*P < 0.05 vs. healthy subjects
**P < 0.01 vs. healthy subjects
***P < 0.001 vs. healthy subjectscellular metabolism and to require high UPS function
[25–27], thus increasing the rate of proteasome-dependent
degradation of misfolded proteins [28]. This is a potential
cause of UPS stress and impaired protein homeostasis, as
frequently found in neoplastic cells [1, 2, 4, 29].
A prominent and constant finding of PaCSs is accu-
mulation of polyubiquitinated proteins [5, 17, 18], which
by itself would suggest proteasome malfunction [30].
However, we also found in PaCSs selective concentration
of proteasome proteins and activity [18, 23], in keeping
with the increase in both polyubiquitinated proteins and
proteasome protein and activity reported in neoplastic
cell lines and primary neoplastic tissues [1, 3, 4, 29]. A
relative insufficiency of proteasome activity in relation to
an excessively high rate of production of polyubiquiti-
nated (misfolded) proteins may explain these findings,
given the evidence for increased activity of E1 ubiquitin-
activating enzyme, which is crucial for protein ubiquiti-
nation, especially in hemopoietic neoplasms [29].
The selective high concentration of multiple chaperone
molecules in PaCSs is of high biological interest. Hsp40
and Hsp70 are known to interact with newly synthesized
proteins as they come off the ribosomes and to enable
their appropriate folding. When folding and repair of mis-
folded and denatured proteins fail, Hsp70 promotes their
ubiquitination and proteasome-dependent degradation
[31]. However, Hsp90 can be recruited to the Hsp70/
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stabilization and prevention of its proteasome degradation
[32–34]. This mechanism involves many mutated or
overexpressed receptor kinases, signaling peptides, and
transcription factors implicated in cancer, which are cha-
peroned by Hsp90 in a way that they can bind their ligand
and undergo persistent activation. In this way, the Hsp90/
oncoprotein complex activates cellular growth signals,
blocks anti-growth signals, sustains angiogenesis, and
evades apoptosis [34–36]. Among targets specifically acti-
vated by Hsp90 in myeloid neoplasms are the BCR-ABL
kinase and several receptor tyrosine kinases, including
TrkA, which stimulate tumor cell proliferation and
survival [34, 37]. Thus, the finding that PaCSs selectively
concentrate Hsp90, Hsp70, and Hsp40 suggests that these
structures are involved in the formation and/or accumula-
tion of the multi-chaperone complexes with high affinity
for client oncoproteins that play a key role in proliferation
of neoplastic clones [33–35]. The Hsp90 inhibitors have
much higher affinity for Hsp90 bound to these complexes
than for uncomplexed Hsp90, resulting in oncoprotein
destabilization and UPS-mediated degradation [33, 34]. In
this context, we hypothesize that the high presence of
PaCSs in certain tumor cells could be associated with a
high sensitivity to Hsp90 inhibitors.
Our findings suggest that when excess PaCSs accumu-
late in the cytoplasm, as in the case of MPN, the cells
can activate two distinct processes to remove high levels
of potentially toxic, polyubiquitinated misfolded pro-
teins, namely: autophagic degradation, or extracellular
discharge through PaCS-filled blebs, generating cyto-
plasmic vesicles (ectosomes). Autophagy was a consist-
ent finding only in neoplastic myeloid cells, while
PaCSs-filled, UPS-rich blebs and vesicles were released
frequently also by non-hematological neoplastic cells
[17] and by non-neoplastic, especially immunocompe-
tent cells [23]. This may represent a sort of non-
canonical secretory discharge system, shown to operate
in intercellular communication among neoplastic and
immunocompetent cells [13, 15, 38]. In particular, the
significant increase in plasma proteasome content in
CML patients who also had increased PaCSs as well as
increased proteasome content in their leukemic cells
suggests that release of UPS-rich PaCS content is a
source of plasma proteasome. This fits with the previ-
ously reported higher plasma proteasome content of
myeloid compared to lymphoid leukemia or plasma cell
myeloma [9]. Although in principle, tumor cell lysis or
apoptosis may explain in part such increased proteasome
plasma levels, parallel measurement of lactate dehydro-
genase, and other biological markers of cell damage fails
to account for changes in proteasome levels [8, 9]. We
failed to detect signs of apoptosis in most PaCS-storing
cells, with or without associated blebs or vesicles. Thisleaves room for a more specific, cell-type-restricted mech-
anism such as plasma membrane vesicle release, which
has been found to be selectively regulated in several exper-
iments [14]. In principle, this mechanism of PaCSs dis-
charge through ectosomal microvesicle release may also
contribute to the non-canonical, possibly exosome-
mediated Hsp90 secretion that occurs in neoplastic cells
and enhances their invasive potential [39, 40].
Conclusions
This study demonstrates for the first time that PaCSs
accumulate in cells of myeloid neoplasms; in particular,
these structures were widespread in granulocytic cells,
megakaryocytes, and platelets of patients with MPN.
PaCSs development was associated with excess accumu-
lation of proteasome and polyubiquitinated proteins,
likely indicating impairment of the UPS-dependent pro-
tein homeostasis. The selective concentration in PaCSs
of Hsp40, Hsp70, and Hsp90 suggests a role for these
structures in the formation of the multi-chaperone com-
plexes involved in Hsp90-mediated leukemogenesis. In
addition, a microvesicle release mechanism of PaCSs dis-
charge by leukemic cells has been observed, which may
contribute to the increased plasma proteasome found in
MPN and MDS. Definition of the role of PaCSs in myeloid
neoplasms is worth of further investigation, as it may open




This study included 29 patients affected by different forms
of myeloid neoplasms. Four patients with chronic B-cell
leukemia or plasma cell myeloma were also investigated.
Table 1 summarizes the baseline characteristics of the pa-
tients and the samples that were investigated for the pres-
ence of PaCSs. Twenty-six patients were investigated at a
time when they were free from any specific treatment for
the hematological disease. Three patients were studied at
relapse: they were two subjects with CML relapsed after
tyrosine kinase inhibitors and one AML patient relapsed
after conventional chemotherapy. In all the cases, BM bi-
opsy was performed as part of the diagnostic workup. BM
biopsies from six individuals without any apparent BM
pathology were also investigated. In two cases, BM biopsy
was taken from the femoral head that was removed during
surgery for hip prosthesis in patients with osteoarthritis.
In four cases, iliac BM biopsies were taken as part of the
staging procedure for non-Hodgkin’s or Hodgkin’s lymph-
oma and were free from the lymphoproliferative disease
after histological and immunophenotypic BM examin-
ation. Control PB samples were obtained from healthy
volunteers. Granulocyte, mononuclear cell, and platelet
fractions were separated from PB samples as previously
Pecci et al. Journal of Hematology & Oncology  (2015) 8:71 Page 9 of 11reported [20]. The study subjects or their legal guardians
gave informed consent for this study, which was approved
by the Institutional Review Board of the IRCCS Policlinico
San Matteo Foundation, Pavia, Italy.
Electron microscopy and immunogold analysis
BM biopsies or PB cell preparations were fixed immedi-
ately after sampling in 2.5 % glutaraldehyde and 2 % para-
formaldehyde in pH 7.3 cacodylate buffer for 4 h at 4 °C,
followed by post-fixation in 1.5 % osmium tetroxide for 1 h
at room temperature, and Epon-Araldite embedding [18].
Ultrathin sections (~70 nm thick) were cut from the resin
blocks and stained with uranyl acetate/lead citrate for con-
ventional electron microscopy or underwent immunogold
staining as previously reported [17, 23]. Sections were
incubated in 10 % normal goat or bovine serum (Dako,
Glostrup, Denmark) for 1 h at room temperature, followed
by incubation with primary antibodies (as specified below)
and secondary anti-mouse, anti-rabbit, or anti-goat IgG or
IgM labeled with 6-, 10-, 15-, or 20-nm gold particles (Aur-
ion ImmunoGold Reagents, Wageningen, Netherlands; or
BB International, Cardiff, UK). Sections were counter-
stained with uranyl acetate/lead citrate. Specimens were
analyzed by a Jeol JEM-1200 EX II (JEOL Ltd, Tokyo,
Japan) transmission electron microscope equipped with an
Olympus Mega View III CCD camera (Tokyo, Japan). The
following primary antibodies were used: mouse FK1 mono-
clonal against polyubiquitinated proteins [41] (Enzo Life
Sciences International, Plymouth Meeting, PA, USA);
rabbit polyclonal against the 20S proteasome, αβ or β5i
subunits (Calbiochem, La Jolla, CA, USA); rabbit poly-
clonal against 19S proteasome, S2 subunit (Calbiochem);
rabbit polyclonal against Hsp40 (LS Bio, Seattle, WA,
USA); goat polyclonal against Hsp70 (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA); mouse 4F3-E8 monoclonal
against Hsp90 (Novus Biologicals, Littleton, CO, USA);
rabbit polyclonal against BAG6 (Santa Cruz Biotechnol-
ogy); rabbit polyclonal against LC3A (Abgent, San Diego,
CA, USA). The specificity of immunogold labeling was
evaluated by omitting the specific antibodies in the first
layer of the procedure or by substituting them with non-
immune IgG or IgM (Santa Cruz Biotechnology) or unre-
lated antibodies.
Software-assisted image analysis
Image analysis was carried out on PB granulocyte and
platelet electron microscopy preparations from 4 con-
secutive patients affected by CML (patients 3–6 in
Table 1) and three healthy subjects. Patient samples were
collected and processed for TEM simultaneously with
control samples in three different experiments. Sections
were analyzed after immunogold staining with the FK1
antibody against polyubiquitinated proteins. Images were
taken at a 25,000× magnification, and a mean number of25.7 ± 1.8 granulocyte sections and 65 ± 10.2 platelet
sections were analyzed for each subject. Morphometric
observations were carried out by the ITEM soft imaging
system (Olympus Soft Imaging Solutions GmbH). The
following parameters were directly measured: presence,
number, and area of each individual PaCS; area of the
cytoplasm of each analyzed cell; and number of immuno-
gold particles inside PaCSs and in the cytoplasm outside
PaCSs. Data were expressed as means ± SD. Statistical
analysis was performed by two-tailed Student’s t test.
Immunofluorescence analysis
Semithin (about 0.1 μm) ultramicrotomic sections were
obtained from the resin blocks and used for immuno-
fluorescence confocal and phase contrast microscopy.
After washing with PBS, sections were incubated over-
night with primary and then with secondary antibodies
as described [23]. Primary antibodies against 19S, 20S,
and polyubiquitinated proteins are the same used for
electron microscopy. Secondary antibodies were Alexa
Fluor 488-conjugated anti-mouse or anti-rabbit IgG (Life
technologies, Paisley, UK). Specimens were analyzed by a
TCS SP5II confocal laser scanning microscope equipped
with PL APO 40x/1.25 NA and 63/1.40 NA oil-immersion
objectives (Leica, Heidelberg, Germany).
Western blotting analysis
Granulocytes and platelets lysates were prepared and
dissociated as previously described [20].
Equal amounts of samples were separated in a 12 %
polyacrylamide SDS-PAGE gel and transferred to nitrocel-
lulose (Bio-Rad, Hercules, CA, USA). After blocking with
5 % not-fat milk, membranes were probed with mouse
monoclonal MCP against proteasome 20S α6 subunit
(Enzo Life Sciences) or mouse monoclonal AC-15 against
β-actin (Sigma, St. Louis, MO, USA). Membranes were
then incubated with horseradish peroxidase-conjugated
anti-mouse antibody, and protein bands were visualized
by an enhanced chemiluminescence method (GE Health-
care, Waukesha, WI, USA).
ELISA of plasma proteasome levels
Plasma samples were obtained by centrifugation of whole
blood anti-coagulated with citrate for 15 min at 1000 g
and maintained at –20 °C until analysis. The proteasome
levels were measured by the 20S/26S Proteasome ELISA
Kit (Enzo Life Sciences). Plasma samples were diluted 1:8
with the ELISA buffer provided by the kit and assayed in
duplicate. Optical density was read at 450 nm on a
microplate reader (Model 680; Bio-Rad, Hercules, CA,
USA). Data are representative of three separate mea-
surements. Statistical analysis was performed by two-
tailed Student’s t test.
Pecci et al. Journal of Hematology & Oncology  (2015) 8:71 Page 10 of 11Additional file
Additional file 1: Supplementary figures. Figure S1. No PaCSs are
found in chronic B-cell leukemia and plasma cell myeloma. Figure S2.
PaCSs are not found in non-neoplastic BM cells, whereas some PaCSs are
identified in PB granulocytes and platelets from healthy subjects.
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